Wave Life Sciences, Inc. (WVE) Stock Price & How to Invest
Last updated November 2026
Short answer
Wave Life Sciences (WVE) is a clinical-stage RNA medicines company whose stock has fallen from a ~$21.73 high to ~$2.65 (November 20, 2026), down ~83% this year, after its obesity drug WVE-007 produced only ~0.9% placebo-adjusted weight loss at six months. At a ~$524 million market cap against ~$431 million of cash, investors are now paying roughly $93 million for the pipeline, GSK partnership and RNA editing platform. It is a binary, data-driven stock.
WVE stock price
As of 2026-11-20, Wave Life Sciences, Inc. (WVE) last closed at $2.56, down 63.7% over the past year. Over the past 52 weeks it has traded between $2.56 and $21.31.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Wave Life Sciences, Inc.'s investor relations page. Walnut is informational, not investment advice.
WVE key stats
At $2.56 on November 20, 2026, Wave Life Sciences, Inc. (WVE) has a market cap of $505M.
- Market cap
- $505M
- Price to book
- 1.3
Market cap, P/E and yield are measured at the $2.56 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Wave Life Sciences, Inc. (WVE)?
The last two weeks for Wave Life Sciences, Inc., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- WVE closed at $2.56 on November 20, 2026, down 18.2% over the past five trading days (from $3.13).
- On November 12, 2026, Citigroup lowered its target to $15.00 from $19.00 (Buy).
- On November 9, 2026, B. Riley Securities lowered its target to $18.00 from $22.00 (Buy).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Wave Life Sciences, Inc. (WVE) do?
Wave Life Sciences builds oligonucleotide medicines, short synthetic strands of genetic material that silence, edit or splice RNA inside cells. Its PRISM platform spans GalNAc-siRNA (the SpiNA design), RNA editing (AIMers, which recruit the body's own ADAR enzymes to correct a single RNA letter) and splicing. The lead programs are WVE-007, an INHBE-silencing siRNA for obesity; WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD); and WVE-008, an editing program for PNPLA3 I148M liver disease. Older programs in Duchenne (WVE-N531) and Huntington's (WVE-003) are being offered to partners. In August 2026 the company redomiciled from Singapore to Delaware, becoming Wave Life Sciences, Inc.
The stock's story in 2026 is a round trip. In December 2025, three-month WVE-007 data showing ~9.4% visceral fat loss and a ~3.2% lean mass gain sent shares soaring, and Wave raised ~$350 million. On March 26, 2026, six-month data showed only ~0.9% placebo-adjusted weight loss and no clear benefit from a higher dose; the stock fell roughly 50% in a day. A weak second quarter (revenue of ~$2.3 million versus estimates near $7.5 million) and steady selling took it to a ~$3.04 low in October. Third-quarter revenue, reported October 27, was ~$13.2 million, all from the GSK collaboration and ahead of the ~$9.9 million consensus, against a net loss of ~$61.9 million (EPS of -$0.30 versus ~-$0.32 expected). Cash and marketable securities stood at ~$431 million on September 30, 2026, which management says funds operations into the third quarter of 2028. On November 13, ahead of ObesityWeek, Wave reported six-month data from the 600 mg single-dose cohort: an 88% mean maximum reduction in Activin E and results similar to the 400 mg dose, with placebo-adjusted reductions in visceral fat and waist circumference, preserved lean mass and total fat relatively unchanged, but no weight-loss figure. The shares fell to new lows afterward, closing at ~$2.65 on November 20, 2026, down ~17% over a month, ~49% over three months, ~83% year to date and ~61% over a year.
The investment picture is now about what the market is not pricing. With roughly 197 million shares at ~$2.65, the market cap is ~$524 million and enterprise value is only ~$93 million. Analysts still average a ~$16.63 target across 19 firms, but targets earlier ranged from ~$10 (Leerink) to ~$44 (Canaccord), which shows how little consensus exists. The next proof points are WVE-006 600 mg monthly-dose data in Q4 2026, six-month data from the high-BMI Phase 2a obesity trial in 2027, the tirzepatide combination trial (which now also carries the maintenance study), and a registrational WVE-006 study after FDA alignment in October 2026.
What's driving Wave Life Sciences, Inc. (WVE)?
1. WVE-006 and the AATD registrational path
WVE-006 is the first RNA editing therapy to show clinical proof of concept in people, correcting the Z mutation in SERPINA1 mRNA so the liver makes functional M-AAT protein. In the RestorAATion-2 trial in Pi*ZZ patients, it produced dose-dependent increases in M-AAT and reductions in Z-AAT with no liver toxicity reported to date. In October 2026 the FDA aligned with a two-year registrational trial using a one-year interim biomarker analysis for possible accelerated approval, and accepted Wave's LC-MS assay for measuring the two protein forms. AATD affects roughly 200,000 people in the US and Europe with the ZZ genotype, and a single program that reaches approval would anchor the valuation.
2. WVE-007 repositioned as a combination and maintenance drug
After the March 2026 readout showed only ~0.9% placebo-adjusted weight loss at six months, Wave reframed WVE-007 around body composition: ~14% visceral fat reduction and preserved or increased lean mass. The 600 mg single-dose cohort, reported in November 2026, looked similar to 400 mg, and the 240 mg cohort kept its visceral fat and waist reductions at one year with no drug-related serious adverse events. Two Phase 2a studies now test the idea. A monotherapy trial is dosing people with a BMI of 35 to 50 at 240 mg or 400 mg, with six-month data expected in 2027. A placebo-controlled trial pairs WVE-007 with weekly tirzepatide against tirzepatide alone in people with type 2 diabetes, and Wave has folded its planned post-incretin maintenance study into it to speed the readout. If a once or twice yearly shot can hold weight off after a GLP-1 is stopped, the obesity option is far from dead.
3. GSK collaboration revenue and milestones
All of Wave's revenue comes from its collaboration with GSK (signed in December 2022), which pays for research, milestones and eventually royalties. Nine-month 2026 revenue was ~$53.7 million, up from ~$25.5 million a year earlier, and trailing twelve-month revenue is ~$71 million. In September 2026, GSK selected a hepatology development candidate built on Wave's SpiNA siRNA design, triggering a ~$12 million milestone payable in Q4 2026. Three more GSK programs are approaching candidate selection, and each is eligible for ~$330 to $375 million in milestones plus tiered royalties. Revenue is lumpy (Q2 2026 was only ~$2.3 million), but this partnership is outside validation that the chemistry works.
4. A deep cash cushion and a cheap enterprise value
Wave held ~$431 million in cash and marketable securities on September 30, 2026, excluding the pending GSK milestone, and guides to a runway into the third quarter of 2028. Quarterly operating expenses run ~$79 million, so the cushion covers roughly seven quarters of burn before any partner income. With a ~$524 million market cap on November 20, 2026, the enterprise value is ~$93 million, a low figure for a company with clinical RNA editing data, a big pharma partner and multiple readouts into 2027. The flip side is that the shelf registration remains active, so a strong data release could again be paired with an equity raise, as happened in December 2025.
What are the risks to Wave Life Sciences, Inc. (WVE)?
The central risk is that WVE-007 never produces meaningful weight loss. The Phase 1 data showed body composition changes but little movement on the scale, and the high-BMI Phase 2a and the tirzepatide combination trial may confirm that, which would remove most of the obesity value the market once assigned. WVE-006 must show durable M-AAT levels in larger, longer trials, and competing approaches from Beam Therapeutics and Korro Bio could reach the clinic or market with stronger data. Revenue depends on a single partner, GSK, and its timing is unpredictable, as the ~$2.3 million second quarter showed. Operating expenses rose to ~$79 million a quarter in Q3 2026 and the company has an accumulated deficit of ~$1.48 billion, so further dilution is likely before any product revenue arrives. Law firm Johnson Fistel has advertised an investigation tied to the March 26, 2026 drop, but the October 2026 10-Q states Wave is not party to any material legal proceedings. At ~$2.65 the stock is volatile and sensitive to every data update; it kept falling after the November 2026 ObesityWeek update, which again gave no weight-loss figure.
What is the Wave Life Sciences, Inc. (WVE) forecast?
19 analysts publish price targets on WVE, averaging $16.63 as of November 2026, or +549.6% against the $2.56 share price on November 20, 2026. The published targets run from $10.00 to $44.00, a wide spread, and the ratings split 19 buy, 2 hold, 0 sell. Over the last six months there has been 1 raise and 8 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full WVE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is WVE a buy or a sell?
We give no verdict on Wave Life Sciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. WVE-006 and the AATD registrational path. WVE-006 is the first RNA editing therapy to show clinical proof of concept in people, correcting the Z mutation in SERPINA1 mRNA so the liver makes functional M-AAT protein. The most optimistic published target, $44.00, assumes this works close to its best case.
The case against. The central risk is that WVE-007 never produces meaningful weight loss. The most pessimistic target, $10.00, is roughly what WVE is worth if this bites instead.
Read the full bull and bear case on WVE, including what would have to change to break either one. Walnut is not an investment adviser.
How is Wave Life Sciences, Inc. (WVE) valued?
Market cap, P/E and dividend yield at today's price are in the WVE key stats above. The business figures below come from Wave Life Sciences, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$71 million
- Q3 2026 revenue: ~$13.2 million vs ~$9.9 million expected
- Q3 2026 EPS: -$0.30 vs ~-$0.32 expected
- Net loss (TTM): ~-$211 million
- Cash and securities: ~$431 million (Sept 30, 2026)
- Enterprise value: ~$93 million
As of November 2026: Wave has no product revenue, so earnings multiples do not apply; the useful lens is enterprise value against pipeline and cash. At ~$2.65 on November 20, 2026, the market cap is ~$524 million, and subtracting ~$431 million of cash leaves ~$93 million for everything else, about 1.3x trailing collaboration revenue and about 1.3 times book value overall. Net loss per share was ~$0.30 in Q3 2026, and analysts expect about -$1.09 for 2026. Analyst targets average ~$16.63, showing that the valuation hinges almost entirely on how WVE-006 and WVE-007 data land.
Who competes with Wave Life Sciences, Inc. (WVE)?
Obesity and INHBE challengers
Eli Lilly (tirzepatide) and Novo Nordisk (semaglutide) set the bar Wave's obesity drug is measured against, with ~15% to 20% weight loss. Arrowhead Pharmaceuticals is developing its own INHBE siRNA, and Regeneron published the human genetics behind INHBE. Muscle-sparing programs such as Regeneron's and Scholar Rock's compete for the same body-composition pitch.
AATD treatments
Beam Therapeutics (BEAM-302, base editing) and Korro Bio (RNA editing) chase the same goal as WVE-006: correcting the Z mutation so patients make normal protein. Takeda and Arrowhead's fazirsiran targets the liver side of the disease, while Grifols, CSL and Takeda sell weekly infused augmentation therapy, the current standard.
RNA medicine platforms
Alnylam Pharmaceuticals is the reference siRNA company, with approved products and a large GalNAc liver franchise, while Arrowhead and Ionis Pharmaceuticals compete for the same pharma partnerships and liver targets. ProQR and Korro Bio are the closest RNA editing peers, and Sarepta competes with WVE-N531 in exon-skipping for Duchenne.
What stocks are similar to Wave Life Sciences, Inc. (WVE)?
Other names that sit close to WVE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Wave Life Sciences, Inc. (WVE)
There are three common ways to get WVE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so WVE sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where WVE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Wave Life Sciences, Inc. (WVE)
WVE is a cash-backed but deeply discounted RNA platform bet, trading barely above its cash in November 2026. The obesity thesis broke in March 2026; what is left depends on WVE-006 in AATD, GSK milestones and the Phase 2a obesity data due in 2027.
More on Wave Life Sciences, Inc. (WVE)
Whether WVE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is WVE a buy or a sell?, and where the stock could go from here in the WVE stock forecast.
For income investors, whether WVE pays a dividend and how the payout looks is covered in does WVE pay a dividend? And to weigh WVE against a peer, read the full side-by-side comparisons: WVE vs LLY and WVE vs NVO.
Wondering how WVE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Wave Life Sciences, Inc.
Ask Walnut's AI anything about WVE and see how it fits what you own.
FAQ
Why did Wave Life Sciences stock fall so much in 2026?
+
The main blow came on March 26, 2026, when six-month data from the Phase 1 INLIGHT trial of WVE-007 showed only ~0.9% placebo-adjusted weight loss and no clear benefit from the higher 240 mg dose compared with lower doses. Investors had bid the stock up to a ~$21.73 high on hopes of a once or twice yearly obesity shot, and shares fell roughly 50% in a day, to ~$6.20. The decline then continued: second-quarter revenue of ~$2.3 million missed estimates near $7.5 million, several analysts cut price targets, and the stock made new lows through the autumn. A November 13 update on the 600 mg cohort again reported body-composition changes without a weight-loss number, and on November 20, 2026 the shares closed at ~$2.65, about 88% below the 52-week high, ~83% lower year to date and ~61% lower than a year ago.
Has a class action lawsuit been filed against Wave Life Sciences?
+
As of late October 2026, no filed securities class action against Wave Life Sciences has surfaced. The law firm Johnson Fistel has issued repeated press releases since March 26, 2026, saying it is investigating whether Wave or its executives violated federal securities laws in connection with the WVE-007 data and the share price drop. An investigation notice is a solicitation for clients, not a lawsuit, and no court docket or case number has been reported. Wave's quarterly report filed with the SEC on October 27, 2026 states that the company is not currently a party to any material legal proceedings. A suit could still be filed later, so this remains a risk worth monitoring and not a settled matter.
What does Wave Life Sciences actually do?
+
Wave designs oligonucleotides, short chemically modified strands of nucleic acid that act on RNA inside cells. Its PRISM platform controls the 3D shape (stereochemistry) of each strand, which the company says improves potency and durability. It uses that chemistry three ways: siRNA to silence genes (WVE-007 for obesity and the GSK programs), RNA editing to correct a single faulty letter in RNA (WVE-006 for AATD and WVE-008 for liver disease), and splicing or allele-selective drugs for rare neurological and muscle diseases (WVE-N531 and WVE-003, now offered for partnering). Wave does not sell any product. All revenue comes from its research collaboration with GSK, and it is headquartered in Cambridge, Massachusetts after redomiciling from Singapore to Delaware in August 2026.
How much cash does Wave have, and how long will it last?
+
Wave reported ~$431 million in cash, cash equivalents and marketable securities on September 30, 2026: ~$197 million in cash and ~$233 million in short-term securities. That excludes a ~$12 million GSK milestone expected in Q4 2026 and any future partner payments. Management guides to a cash runway into the third quarter of 2028. Quarterly operating expenses were ~$79 million in Q3 2026 (~$54 million R&D and ~$25 million G&A), partly offset by collaboration revenue and ~$4 million of interest income. The 10-Q includes no going-concern warning. Most of today's cushion came from a ~$350 million equity raise in December 2025, completed when the shares traded far above today's ~$2.65.
Is WVE-007 still a viable obesity drug?
+
It is too early to say, which is why the stock is so cheap. The Phase 1 data showed what Wave calls a quality-of-weight-loss profile: ~14% visceral fat reduction and preserved or slightly increased lean muscle at six months, but only ~0.9% placebo-adjusted weight loss. The 600 mg single-dose cohort, reported November 13, 2026, cut Activin E by 88% at its maximum and looked similar to 400 mg, with total fat relatively unchanged. Those trial participants had relatively modest obesity (average BMI 31.7), and the new Phase 2a cohort enrolls people with a BMI of 35 to 50, where more fat is available to lose, with six-month data expected in 2027. Wave is also testing WVE-007 alongside tirzepatide, where preserving muscle could matter, and has merged its planned maintenance study into that trial. If none of these show a clear effect, the obesity thesis is largely over.
What is WVE-006 and why does it matter?
+
WVE-006 is an RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, a genetic disease in which a single mutation (the Z allele) makes the liver produce a misfolded protein that damages the liver and leaves the lungs unprotected. WVE-006 uses the body's ADAR enzyme to correct that letter in the RNA, so the liver makes normal M-AAT protein instead. In the RestorAATion-2 trial it raised M-AAT and lowered Z-AAT in a dose-dependent way without liver safety issues so far. In October 2026 the FDA agreed with a registrational plan: a two-year trial with a one-year biomarker interim that could support accelerated approval. For many analysts this is now the most valuable program in the company.
How is Wave Life Sciences valued compared to its cash?
+
At ~$2.65 per share on November 20, 2026, Wave's market cap is ~$524 million (slightly more if ~7 million pre-funded warrants are counted). Subtracting ~$431 million of cash and securities gives an enterprise value of ~$93 million. That is the price the market assigns to WVE-006, WVE-007, WVE-008, the GSK partnership with three more programs nearing selection, and the PRISM platform. The low figure reflects heavy skepticism after the obesity data and ongoing losses of ~$210 million a year. The average analyst price target of ~$16.63 across 19 firms implies most covering analysts see more value, but the earlier spread from ~$10 to ~$44 shows how wide the range of outcomes is.
What are the next catalysts for WVE stock?
+
Wave held a virtual Research Day on November 4, 2026 focused on WVE-008 and PNPLA3 liver disease, and released 600 mg WVE-007 data on November 13 ahead of ObesityWeek. Still expected in Q4 2026 are WVE-006 data from the 600 mg monthly multidose cohort, a clinical trial application for WVE-008, and receipt of the ~$12 million GSK milestone. Into 2027, six-month data from the high-BMI Phase 2a obesity trial should arrive, the tirzepatide combination trial (now including the maintenance study) continues, the WVE-006 registrational trial should begin, and GSK may select more candidates. Each of these could move a ~$2.65 stock sharply in either direction. Walnut is not an investment adviser; these are descriptions, not recommendations.
How did Wave Life Sciences do in its latest quarter?
+
For the third quarter of 2026, reported October 27, Wave posted ~$13.2 million of revenue, all from its GSK collaboration and above the ~$9.9 million consensus, with a net loss of ~$61.9 million, or -$0.30 a share versus ~-$0.32 expected. Operating expenses were ~$79 million. It ended September with ~$431 million of cash and securities and kept its runway guidance into the third quarter of 2028. Analysts expect fourth-quarter revenue of about $9.9 million and a loss near $0.32 a share.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Wave Life Sciences, Inc.'s investor relations page or your broker before making investment decisions.